Knowledge, views and experiences of Australian optometrists in relation to ocular stem cell therapies

ABSTRACT

Clinical relevance

Findings from this study examining Australian optometrists’ insights into ocular stem cell (SC) therapies have capacity to inform continuing professional development (CPD) about these interventions.

Background

This study investigated Australian optometrists’ knowledge, views, experiences, and preferred education sources regarding ocular SC therapies.

Methods

An online survey was distributed to optometrists via Optometry Australia, Mivision magazine, professional groups, and social media from August 2020 to March 2021. Data were collected on demographics, and SC knowledge, awareness and experience.

Results

Of 81 optometrists who completed the survey, many were metropolitan-based (85%), worked in independent practice (47%), female (56%) and >46 years of age (45%). Approximately one-fifth indicated awareness of ocular SC therapies used in standard practice; one-third had knowledge of SC clinical trials. The most noted SC therapies were for corneal disease in the United States [US] (72%) and Australia (44%). Respondents identified the availability of SC therapies for dry eye disease in Australia and the US (39% and 44% respectively), despite no regulatory-approved treatments for this indication. Clinical trials investigating inherited retinal and corneal diseases in Australia were the most commonly identified (44% and 36%, respectively). Half the respondents felt ‘unsure’ about the quality of evidence for treating eye conditions using SCs. One-fifth indicated concerns with these therapies; of these, most mentioned efficacy (82%), safety (76%) and/or cost (71%). About one-fifth reported being asked for advice about SCs by patients. Two-thirds felt neutral, uncomfortable, or very uncomfortable providing this advice, due to lack of knowledge or the topic being beyond their expertise. Over half (57%) were unsure if clinical management should change if patients received SC therapies. Respondents were receptive to face-to-face education.

Conclusion

Some optometrists responding to this survey were aware of ocular SC therapies and/or clinical trials. CPD programs may assist with maintaining currency in this evolving field.

KEYWORDS:

• Cornea
• optometry
• regenerative medicine
• retina
• stem cell

Acknowledgement

We acknowledge the assistance of Optometry Australia, Mivision magazine, Cornea and Contact Lens Society of Australia; OPSM in Victoria, Tasmania, Queensland, Northern Territory and North New South Wales; and UNSW School of Optometry and Vision Science for distributing the survey to its members.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Supplementary material

Supplemental data for this article can be accessed online at https://doi.org/10.1080/08164622.2022.2102409

Additional information

Funding

This project was funded through the Stem Cells Australia – MRFF Accelerated Research Stem Cells Grant (2019–2021).